dekavil
Phase 1- Indications
- Rheumatoid arthritis
Company intelligence / Profile preview
Hospira was the world leader in generic injectable pharmaceuticals and infusion technologies with a growing biosimilars business. It had a broad commercial portfolio serving hospitals globally. The company expanded rapidly through acquisitions such as Mayne Pharma and Orchid’s injectable business. In September 2015, it was acquired by Pfizer for $17 billion to strengthen Pfizer's global established pharmaceutical business with leading positions in sterile injectables and biosimilars.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hospira, Inc..